Teva Pharmaceutical Industries Ltd. ADR's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), Teva Pharmaceutical Industries Ltd. ADR reported revenue of $17.3B (+4.3% year on year) and net income of $1.4B (+172.4% year on year).
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Net revenues | $17.3B | $16.5B | $15.8B | $14.9B |
| Cost of sales | $8.3B | $8.5B | $8.2B | $8.0B |
| Gross profit | $8.9B | $8.1B | $7.6B | $7.0B |
| Research and development expenses, net | $1.0B | $998.0M | $953.0M | $838.0M |
| Selling and marketing expenses | $2.7B | $2.5B | $2.3B | $2.3B |
| General and administrative expenses | $1.3B | $1.2B | $1.2B | $1.2B |
| Intangible assets impairments | $259.0M | $251.0M | $350.0M | $355.0M |
| Goodwill impairment | $0 | $1.3B | $700.0M | $2.0B |
| Other asset impairments, restructuring and other items | $1.1B | $1.4B | $718.0M | $414.0M |
| Legal settlements and loss contingencies | $467.0M | $761.0M | $1.0B | $2.1B |
| Other loss (income) | $18.0M | ($14.0M) | ($49.0M) | ($107.0M) |
| Operating income (loss) | $2.2B | ($303.0M) | $433.0M | ($2.1B) |
| Financial expenses – net | $934.0M | $981.0M | $1.1B | $966.0M |
| Income (loss) before income taxes | $1.2B | ($1.3B) | ($624.0M) | ($3.1B) |
| Income taxes (benefit) | ($180.0M) | $676.0M | ($7.0M) | ($638.0M) |
| Share in (profits) losses of associated companies – net | ($15.0M) | ($1.0M) | ($2.0M) | ($21.0M) |
| Net income (loss) | $1.4B | ($2.0B) | ($615.0M) | ($2.4B) |
| Net income (loss) attributable to redeemable and non-redeemable non-controlling interests | $7.0M | ($320.0M) | ($56.0M) | ($53.0M) |
| Net income (loss) attributable to Teva | $1.4B | ($1.6B) | ($559.0M) | ($2.4B) |
| Basic | $1.23 | -$1.45 | -$0.50 | -$2.12 |
| Diluted | $1.21 | -$1.45 | -$0.50 | -$2.12 |
| Basic | 1.1B | 1.1B | 1.1B | 1.1B |
| Diluted | 1.2B | 1.1B | 1.1B | 1.1B |
| Line item | Jun 30, 2026 · Q2 | Mar 31, 2026 · Q1 | Sep 30, 2025 · Q3 | Jun 30, 2025 · Q2 |
|---|---|---|---|---|
| Net revenues | $4.1B | $4.0B | $4.5B | $4.2B |
| Cost of sales | $2.0B | $2.0B | $2.2B | $2.1B |
| Gross profit | $2.2B | $2.0B | $2.3B | $2.1B |
| Research and development expenses | $970.0M | $222.0M | $256.0M | $244.0M |
| Selling and marketing expenses | $717.0M | $696.0M | $656.0M | $654.0M |
| General and administrative expenses | $317.0M | $304.0M | $317.0M | $305.0M |
| Intangible assets impairments | $22.0M | $8.0M | $64.0M | $42.0M |
| Other assets impairments, restructuring and other items | $147.0M | $26.0M | $62.0M | $232.0M |
| Legal settlements and loss contingencies | $230.0M | $72.0M | $60.0M | $166.0M |
| Other loss (income) | ($19.0M) | ($9.0M) | $7.0M | $4.0M |
| Operating income (loss) | ($231.0M) | $652.0M | $882.0M | $455.0M |
| Financial expenses, net | $224.0M | $216.0M | $237.0M | $252.0M |
| Income (loss) before income taxes | ($455.0M) | $437.0M | $646.0M | $203.0M |
| Income taxes (benefit) | $121.0M | $67.0M | $214.0M | ($78.0M) |
| Share in (profits) losses of associated companies, net | ($500.0K) | $1.0M | ($2.0M) | ($1.0M) |
| Net income (loss) | ($575.0M) | $369.0M | $434.0M | $283.0M |
| Net income (loss) attributable to Teva | ($576.0M) | $369.0M | $433.0M | $282.0M |
| Basic | -$0.49 | $0.32 | $0.38 | $0.25 |
| Diluted | -$0.49 | $0.31 | $0.37 | $0.24 |
| Basic | 1.2B | 1.2B | 1.1B | 1.1B |
| Diluted | 1.2B | 1.2B | 1.2B | 1.2B |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Cash and cash equivalents | $3.6B | $3.3B | $3.2B | $2.8B |
| Accounts receivables, net of allowance for credit losses of $81 million and $78 million as of December 31, 2025 and December 31, 2024, respectively | $3.7B | $3.1B | $3.4B | $3.7B |
| Inventories | $3.2B | $3.0B | $4.0B | $3.8B |
| Prepaid expenses | $1.1B | $1.0B | $1.3B | $1.2B |
| Other current assets | $539.0M | $409.0M | $504.0M | $549.0M |
| Assets held for sale | $1.8B | $1.8B | $70.0M | $10.0M |
| Total current assets | $13.9B | $12.6B | $12.5B | $12.1B |
| Deferred income taxes | $2.2B | $1.8B | $1.8B | $1.5B |
| Other non-current assets | $405.0M | $462.0M | $470.0M | $441.0M |
| Property, plant and equipment, net | $4.1B | $4.6B | $5.8B | $5.7B |
| Operating lease right-of-use assets | $345.0M | $367.0M | $397.0M | $419.0M |
| Identifiable intangible assets, net | $3.8B | $4.4B | $5.4B | $6.3B |
| Goodwill | $16.0B | $15.1B | $17.2B | $17.6B |
| Total assets | $40.7B | $39.3B | $43.5B | $44.0B |
| Short-term debt | $1.8B | $1.8B | $1.7B | $2.1B |
| Sales reserves and allowances | $4.1B | $3.7B | $3.5B | $3.8B |
| Accounts payables | $2.5B | $2.2B | $2.6B | $1.9B |
| Employee-related obligations | $739.0M | $624.0M | $611.0M | $566.0M |
| Accrued expenses | $2.7B | $2.8B | $2.8B | $2.2B |
| Other current liabilities | $1.2B | $1.0B | $1.1B | $1.0B |
| Liabilities held for sale | $354.0M | $698.0M | — | — |
| Total current liabilities | $13.5B | $12.8B | $12.2B | $11.5B |
| Deferred income taxes | $296.0M | $483.0M | $606.0M | $548.0M |
| Other taxes and long-term liabilities | $3.8B | $4.0B | $4.0B | $3.8B |
| Senior notes and loans | $15.0B | $16.0B | $18.2B | $19.1B |
| Operating lease liabilities | $288.0M | $296.0M | $320.0M | $349.0M |
| Total long-term liabilities | $19.4B | $20.8B | $23.1B | $23.8B |
| Total liabilities | $32.8B | $33.6B | $35.4B | $35.3B |
| Redeemable non-controlling interests | $0 | $340.0M | — | — |
| Ordinary shares of NIS 0.10 par value per share; December 31, 2025 and December 31, 2024: authorized 2,495 million shares; issued 1,257 million shares and 1,240 million shares, respectively | $58000000.00 | $58000000.00 | $57000000.00 | $57000000.00 |
| Additional paid-in capital | $28.1B | $27.8B | $27.8B | $27.7B |
| Accumulated deficit | ($13.8B) | ($15.2B) | ($13.5B) | ($12.9B) |
| Accumulated other comprehensive loss | ($2.4B) | ($3.1B) | ($2.7B) | ($2.8B) |
| Treasury shares as of December 31, 2025 and December 31, 2024: 107 million ordinary shares | -4.1B | -4.1B | -4.1B | -4.1B |
| Stockholders' equity attributable to Teva shareholders | $7.9B | $5.4B | $7.5B | $7.9B |
| Non-controlling interests | $4.0M | $7.0M | $620.0M | $794.0M |
| Total equity | $7.9B | $5.4B | $8.1B | $8.7B |
| Total liabilities, redeemable non-controlling interests and equity | $40.7B | $39.3B | $43.5B | $44.0B |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Sep 30, 2025 | Jun 30, 2025 |
|---|---|---|---|---|
| Cash and cash equivalents | $3.7B | $3.7B | $2.2B | $2.2B |
| Accounts receivables, net of allowance for credit losses of $75 million and $81 million as of June 30, 2026 and December 31, 2025, respectively | $3.5B | $3.4B | $3.8B | $3.6B |
| Inventories | $3.2B | $3.2B | $3.3B | $3.5B |
| Prepaid expenses | $1.0B | $1.1B | $1.1B | $1.1B |
| Other current assets | $563.0M | $535.0M | $477.0M | $472.0M |
| Assets held for sale | $1.8B | $1.8B | $1.8B | $1.8B |
| Total current assets | $13.8B | $13.7B | $12.7B | $12.6B |
| Deferred income taxes | $2.2B | $2.2B | $1.6B | $1.8B |
| Other non-current assets | $387.0M | $377.0M | $444.0M | $470.0M |
| Property, plant and equipment, net | $3.9B | $4.0B | $4.8B | $4.8B |
| Operating lease right-of-use assets, net | $333.0M | $335.0M | $342.0M | $358.0M |
| Identifiable intangible assets, net | $3.4B | $3.6B | $3.9B | $4.1B |
| Goodwill | $15.8B | $15.8B | $15.9B | $15.9B |
| Total assets | $39.9B | $40.0B | $39.9B | $40.1B |
| Short-term debt | $4.5B | $2.6B | $24.0M | $464.0M |
| Sales reserves and allowances | $3.9B | $3.7B | $4.1B | $4.0B |
| Accounts payables | $2.7B | $2.6B | $2.4B | $2.5B |
| Employee-related obligations | $488.0M | $555.0M | $561.0M | $481.0M |
| Accrued expenses | $2.7B | $2.6B | $3.0B | $3.1B |
| Other current liabilities | $987.0M | $1.1B | $1.1B | $940.0M |
| Liabilities held for sale | $313.0M | $334.0M | $324.0M | $334.0M |
| Total current liabilities | $15.6B | $13.5B | $11.5B | $11.9B |
| Deferred income taxes | $289.0M | $273.0M | $399.0M | $440.0M |
| Other taxes and long-term liabilities | $3.8B | $3.7B | $3.7B | $3.9B |
| Senior notes and loans | $12.1B | $14.0B | $16.8B | $16.8B |
| Operating lease liabilities | $282.0M | $280.0M | $283.0M | $296.0M |
| Total long-term liabilities | $16.5B | $18.3B | $21.1B | $21.4B |
| Total liabilities | $32.1B | $31.8B | $32.6B | $33.3B |
| Ordinary shares of NIS 0.10 par value per share; June 30, 2026 and December 31, 2025: authorized 2,495 million shares; issued 1,271 million shares and 1,257 million shares, respectively. | $59000000.00 | $59000000.00 | $58000000.00 | $58000000.00 |
| Additional paid-in capital | $28.3B | $28.2B | $28.0B | $28.0B |
| Accumulated deficit | ($14.0B) | ($13.4B) | ($14.2B) | ($14.7B) |
| Accumulated other comprehensive loss | ($2.5B) | ($2.5B) | ($2.5B) | ($2.4B) |
| Treasury shares as of June 30, 2026 and December 31, 2025: 106 million ordinary shares and 107 million ordinary shares, respectively | -4.1B | -4.1B | -4.1B | -4.1B |
| Stockholders' equity attributable to Teva shareholders | $7.8B | $8.2B | $7.3B | $6.8B |
| Non-controlling interests | $4.0M | $4.0M | $4.0M | $7.0M |
| Total equity | $7.8B | $8.2B | $7.3B | $6.8B |
| Total liabilities and equity | $39.9B | $40.0B | $39.9B | $40.1B |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Net income (loss) | $1.4B | ($2.0B) | ($615.0M) | ($2.4B) |
| Impairment of goodwill | $0 | $1.3B | — | — |
| Impairment of long-lived assets and assets held for sale | $1.0B | $1.3B | — | — |
| Depreciation and amortization | $1.0B | $1.1B | $1.2B | $1.3B |
| Deferred income taxes — net and uncertain tax positions | ($671.0M) | ($634.0M) | ($317.0M) | ($1.1B) |
| Stock-based compensation | $157.0M | $123.0M | $121.0M | $124.0M |
| Net loss (gain) from sale of business and long-lived assets | $0 | ($22.0M) | ($41.0M) | $10.0M |
| Other items, net | $81.0M | $560.0M | $61.0M | ($91.0M) |
| Net cash provided by (used in) operating activities | $1.6B | $1.2B | $1.4B | $1.6B |
| Beneficial interest collected in exchange for securitized trade receivables | $1.2B | $1.3B | $1.5B | $1.1B |
| Purchases of property, plant and equipment and intangible assets | ($501.0M) | ($498.0M) | ($526.0M) | — |
| Proceeds from sale of business and long lived assets | $34.0M | $43.0M | $68.0M | $68.0M |
| Purchases of investments and other assets | ($57.0M) | ($71.0M) | ($46.0M) | ($1.0M) |
| Proceeds from sale of investments | $42.0M | $40.0M | $0 | $4.0M |
| Acquisitions of businesses, net of cash acquired | $0 | ($15.0M) | $0 | ($7.0M) |
| Other investing activities | $5.0M | $2.0M | ($5.0M) | $0 |
| Net cash provided by (used in) investing activities | $737.0M | $792.0M | $968.0M | $656.0M |
| Repayment of senior notes and loans and other long term liabilities | ($4.1B) | ($1.6B) | ($4.2B) | ($1.4B) |
| Proceeds from senior notes, net of issuance costs | $2.3B | $0 | $2.5B | $0 |
| Proceeds from short term debt | $0 | $0 | $700.0M | $0 |
| Repayment of short term debt | $0 | $0 | ($700.0M) | $0 |
| Purchase of shares from redeemable and non-redeemable non-controlling interests | -38.0M | -64.0M | — | — |
| Dividends paid to redeemable and non-redeemable non-controlling interests | ($340.0M) | ($78.0M) | — | — |
| Other financing activities | $41.0M | ($8.0M) | ($212.0M) | ($118.0M) |
| Net cash provided by (used in) financing activities | ($2.2B) | ($1.8B) | ($1.9B) | ($1.5B) |
| Translation adjustment on cash, cash equivalents and restricted cash | $21.0M | ($174.0M) | ($30.0M) | ($123.0M) |
| Net change in cash, cash equivalents and restricted cash | $256.0M | $74.0M | $393.0M | $636.0M |
| Balance of cash, cash equivalents and restricted cash at beginning of year | $3.3B | $3.2B | $2.8B | $2.2B |
| Balance of cash, cash equivalents and restricted cash at end of year | $3.6B | $3.3B | $3.2B | $2.8B |
| Cash and cash equivalents | $3.6B | $3.3B | $3.2B | $2.8B |
| Restricted cash included in other current assets | $0 | $0 | $1.0M | $33.0M |
| Total cash, cash equivalents and restricted cash shown in the statement of cash flows | $3.6B | $3.3B | $3.2B | $2.8B |
| Beneficial interest obtained in exchange for securitized trade receivables | $1.3B | $1.3B | $1.4B | $1.2B |
| Dividend declared to non-controlling interests | $0 | $0 | $67.0M | — |
| Interest | $950.0M | $1.0B | $1.1B | $948.0M |
| Other assets | ($1.3B) | ($1.1B) | ($1.5B) | ($828.0M) |
| Trade payables, accrued expenses, employee-related obligations and other liabilities | ($15.0M) | $258.0M | $1.6B | $1.9B |
| Trade receivables net of sales reserves and allowances | ($173.0M) | $245.0M | $12.0M | $334.0M |
| Inventories | $152.0M | $166.0M | ($147.0M) | ($163.0M) |
| Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information | ($1.4B) | ($435.0M) | ($72.0M) | $1.3B |
| Line item | Jun 30, 2026 · YTD | Mar 31, 2026 · Q1 | Sep 30, 2025 · YTD | Jun 30, 2025 · YTD |
|---|---|---|---|---|
| Net income (loss) | ($206.0M) | $369.0M | $937.0M | $503.0M |
| Depreciation and amortization | $480.0M | $239.0M | $742.0M | $494.0M |
| Impairment of long-lived assets and assets held for sale | $122.0M | $10.0M | $255.0M | $177.0M |
| Acquired IPR&D related to Emalex Biosciences, see note 2 | $724.0M | — | — | — |
| Net change in operating assets and liabilities | ($780.0M) | ($617.0M) | ($1.6B) | ($1.0B) |
| Deferred income taxes – net and uncertain tax positions | $3.0M | ($22.0M) | ($76.0M) | ($183.0M) |
| Stock-based compensation | $83.0M | $43.0M | $106.0M | $72.0M |
| Other items | ($36.0M) | ($54.0M) | $122.0M | $94.0M |
| Net loss (gain) from sale of business and long-lived assets | ($20.0M) | ($8.0M) | $0 | $0 |
| Net cash provided by (used in) operating activities | $371.0M | ($40.0M) | $491.0M | $122.0M |
| Beneficial interest collected in exchange for securitized trade receivables | $665.0M | $354.0M | $932.0M | $658.0M |
| Purchases of property, plant and equipment and intangible assets | ($273.0M) | ($168.0M) | ($359.0M) | ($223.0M) |
| Proceeds from sale of business and long-lived assets, net | $46.0M | $42.0M | $34.0M | $26.0M |
| Purchase of Emalex Biosciences outstanding shares, see note 2 | -696.0M | — | — | — |
| Purchases of investments and other assets | ($1.0M) | $0 | ($40.0M) | ($27.0M) |
| Other investing activities | ($3.0M) | $1.0M | $5.0M | $3.0M |
| Net cash provided by (used in) investing activities | ($263.0M) | $229.0M | $572.0M | $437.0M |
| Repayment of senior notes and loans and other long-term liabilities | ($23.0M) | $0 | ($4.1B) | ($3.7B) |
| Repayment of convertible debentures | $0 | ($23.0M) | — | — |
| Purchase of shares from redeemable and non-redeemable non-controlling interests | 0 | 0 | -38.0M | -38.0M |
| Dividends paid to redeemable and non-redeemable non-controlling interests | $0 | $0 | ($340.0M) | ($340.0M) |
| Other financing activities | $35.0M | $36.0M | $1.0M | $3.0M |
| Net cash provided by (used in) financing activities | $12.0M | $13.0M | ($2.2B) | ($1.7B) |
| Effect of exchange rate changes on cash and cash equivalents | ($22.0M) | ($17.0M) | $31.0M | $40.0M |
| Net change in cash and cash equivalents | $99.0M | $185.0M | ($1.1B) | ($1.1B) |
| Balance of cash and cash equivalents at beginning of period | $3.6B | $3.6B | $3.3B | $3.3B |
| Balance of cash and cash equivalents at end of period | $3.7B | $3.7B | — | — |
| Beneficial interest obtained in exchange for securitized accounts receivables | $606.0M | $311.0M | $937.0M | $641.0M |
| Other assets | ($578.0M) | ($302.0M) | — | — |
| Trade payables, accrued expenses, employee-related obligations and other liabilities | ($63.0M) | ($144.0M) | — | — |
| Trade receivables net of sales reserves and allowances | $13.0M | ($78.0M) | — | — |
| Inventories | ($152.0M) | ($93.0M) | — | — |
| Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information | ($780.0M) | ($617.0M) | — | — |
Teva Pharmaceutical Industries Ltd. ADR score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.